Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma
Elias Drakos et al.
CLINICAL CANCER RESEARCH (2007)
The regulation of AMPK β1, TSC2, and PTEN expression by p53:: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways
Zhaohui Feng et al.
CANCER RESEARCH (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Modeling the therapeutic efficacy of p53 restoration in tumors
Carla P. Martins et al.
CELL (2006)
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
Evangelia Peponi et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo
Hans-Guido Wendel et al.
CANCER RESEARCH (2006)
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Kensuke Kojima et al.
BLOOD (2006)
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines
Jordi Camps et al.
LEUKEMIA RESEARCH (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Pathogenesis of mantle-cell lymphoma:: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
V Fernàdez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The coordinate regulation of the p53 and rnTOR pathways in cells
ZH Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
RG Jones et al.
MOLECULAR CELL (2005)
Genome-wide array-based CGH for mantle cell lymphoma:: identification of homozygous deletions of the proapoptotic gene BIM
H Tagawa et al.
ONCOGENE (2005)
Inhibition of Akt increases P27KiP1 levels and induces cell cycle arrest in anaplastic large cell lymphoma
GZ Rassidakis et al.
BLOOD (2005)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
The p53-Mdm2 module and the ubiquitin system
D Michael et al.
SEMINARS IN CANCER BIOLOGY (2003)
Establishment and characterization of a new mantle cell lymphoma cell line, Mino
R Lai et al.
LEUKEMIA RESEARCH (2002)
Share Paper
